Genentech adds to autoimmune pipeline with Parvus deal

In its second deal based on its immunomodulatory platform, Parvus granted Genentech rights to develop and commercialize its Navacim nanoparticle therapeutics to treat inflammatory bowel disease (IBD), autoimmune liver diseases and celiac disease.

Parvus Therapeutics Inc. (Burlingame, Calif.) believes Navacims could offer a comprehensive solution for chronic inflammatory conditions. By transforming T cells targeting self-antigens into Tregs that dampen the immune response, the particles shut down antigen presentation and end autoimmune flares, providing a way to address autoimmunity that doesn't depend on the molecular pathway involved (see "Poacher Turned Gamekeeper")...